{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T14:55:52Z","timestamp":1763477752981,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.esmoop.2023.101559","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T03:10:52Z","timestamp":1682392252000},"page":"101559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Timely course of SARS-CoV-2 infections and vaccinations in patients with hemato-oncological diseases: analysis of a real-life cohort"],"prefix":"10.1016","volume":"8","author":[{"given":"M.J.","family":"Mair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mitterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Buratti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Berchtold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.esmoop.2023.101559_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101559_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101559_bib4","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/ajt.15941","article-title":"COVID-19 in solid organ transplant recipients: initial report from the US epicenter","volume":"20","author":"Pereira","year":"2020","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101559_bib5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in persons with haematological cancers","volume":"34","author":"He","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101559_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.annonc.2021.01.068","article-title":"The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate","volume":"32","author":"Garassino","year":"2021","journal-title":"Monitor. Educate. Ann Oncol"},{"issue":"27","key":"10.1016\/j.esmoop.2023.101559_bib8","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101559_bib9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10269","key":"10.1016\/j.esmoop.2023.101559_bib10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101559_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2021.5437","article-title":"Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations","volume":"8","author":"Mair","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101559_bib12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jamaoncol.2021.7777","article-title":"SARS-CoV-2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents","volume":"8","author":"Fenioux","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101559_bib13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2021.2675","article-title":"Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer","volume":"7","author":"Goshen-Lago","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101559_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.annonc.2021.10.014","article-title":"Seroconversion rate after vaccination against COVID-19 in patients with cancer\u2014A systematic review","volume":"33","author":"Corti","year":"2022","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.esmoop.2023.101559_bib15","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101559_bib16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ccell.2022.04.003","article-title":"Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron","volume":"40","author":"Mair","year":"2022","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101559_bib17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1001\/jamaoncol.2022.1096","article-title":"Breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in vaccinated patients with cancer in the US between December 2020 and November 2021","volume":"8","author":"Wang","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2023.101559_bib18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2021.10.014","article-title":"Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis","volume":"160","author":"Becerril-Gaitan","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101559_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-022-01290-8","article-title":"Risk of SARS-CoV-2 breakthrough infection in vaccinated cancer patients: a retrospective cohort study","volume":"15","author":"Rooney","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.101559_bib20","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S1470-2045(21)00573-8","article-title":"Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study","volume":"22","author":"Pinato","year":"2021","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2023.101559_bib21","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494","article-title":"GISAID: Global initiative on sharing all influenza data \u2013 from vision to reality","volume":"22","author":"Shu","year":"2017","journal-title":"Euro Surveill"},{"issue":"67","key":"10.1016\/j.esmoop.2023.101559_bib22","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.21105\/joss.03773","article-title":"Nextclade: Clade assignment, mutation calling and quality control for viral genomes","volume":"6","author":"Aksamentov","year":"2021","journal-title":"J\u00a0Open Source Softw"},{"key":"10.1016\/j.esmoop.2023.101559_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","article-title":"Adjusting for multiple testing\u2014when and how?","volume":"54","author":"Bender","year":"2001","journal-title":"J\u00a0Clin Epidemiol"},{"author":"S\u00fcdtiroler","key":"10.1016\/j.esmoop.2023.101559_bib24"},{"author":"S\u00fcdtiroler","key":"10.1016\/j.esmoop.2023.101559_bib25"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101559_bib26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2022.6815","article-title":"Association of COVID-19 vaccination with breakthrough infections and complications in patients with cancer","volume":"9","author":"Gong","year":"2022","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2023.101559_bib27","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.21.02419","article-title":"Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative","volume":"40","author":"Song","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101559_bib28","article-title":"Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium","volume":"19","author":"Choueiri","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.esmoop.2023.101559_bib29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejca.2022.01.019","article-title":"Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events \u2013 a retrospective cohort study","volume":"165","author":"Mair","year":"2022","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101559_bib30","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity","volume":"80","author":"Mrak","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.esmoop.2023.101559_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.737300","article-title":"Immunological response against SARS-CoV-2 after BNT162b2 vaccine administration is impaired in allogeneic but not in autologous stem cell transplant recipients","volume":"11","author":"Chiarucci","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101559_bib32","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(22)00273-X","article-title":"Outcomes of the SARS-CoV-2 Omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study","volume":"23","author":"Pinato","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10323","key":"10.1016\/j.esmoop.2023.101559_bib33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0140-6736(22)00017-4","article-title":"Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa: a data linkage study","volume":"399","author":"Wolter","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101559_bib34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.2022016147","article-title":"Patients with CLL have a lower risk of death from COVID-19 in the Omicron era","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"issue":"10332","key":"10.1016\/j.esmoop.2023.101559_bib35","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants in England: a cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101559_bib36","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1473-3099(22)00154-2","article-title":"Risk of hospitalisation associated with infection with SARS-CoV-2 Omicron variant versus Delta variant in Denmark: an observational cohort study","volume":"22","author":"Bager","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101559_bib37","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3390\/vaccines10091483","article-title":"A\u00a0lesson from the green pass experience in Italy: a narrative review","volume":"10","author":"Campanozzi","year":"2022","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101559_bib38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.6004\/jnccn.2020.7560","article-title":"Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal","volume":"18","author":"Ueda","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.esmoop.2023.101559_bib39","first-page":"11","article-title":"Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave","volume":"8","author":"Lee","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2023.101559_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01667","article-title":"Pandemic phase-adjusted analysis of COVID-19 outcomes reveals reduced intrinsic vulnerability and substantial vaccine protection from severe acute respiratory syndrome coronavirus 2 in patients with breast cancer","author":"Tagliamento","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101559_bib41","article-title":"Should COVID vaccines be given yearly? Proposal divides US scientists","author":"Kozlov","year":"2023","journal-title":"Nature"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923007858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923007858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:26Z","timestamp":1761856166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923007858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2059702923007858"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101559","relation":{},"ISSN":["2059-7029"],"issn-type":[{"type":"print","value":"2059-7029"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Timely course of SARS-CoV-2 infections and vaccinations in patients with hemato-oncological diseases: analysis of a real-life cohort","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101559"}}